Stocky turns companies like DAI Nippon Pharmaceutical into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Cautious. DNPUF shows modest growth characteristics (55/100 Compounder Score) with reasonable valuation (6.5× forward P/E), but leadership alignment is middling (59/100) and financial defenses are thin—adequate but not robust. The company lacks the operational momentum or capital discipline to justify conviction at this stage.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for DAI Nippon Pharmaceutical:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 54/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates DAI Nippon Pharmaceutical (DNPUF) at 54/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. DNPUF shows modest growth characteristics (55/100 Compounder Score) with reasonable valuation (6.5× forward P/E), but leadership alignment is middling (59/100) and financial defenses are thin—adequate but not robust. The company l
DNPUF's current Stocky Verdict is 54/100, placing it in the "Cautious" band. This composite combines a 55/100 Compounder score, 59/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for DAI Nippon Pharmaceutical yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
DAI Nippon Pharmaceutical scores 59/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
DAI Nippon Pharmaceutical's Vulnerability Profile scores 50/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to DAI Nippon Pharmaceutical.
Sign up free and unlock the full analysis on DNPUF — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for DNPUF in the app.
